Weighing up the cost of switching to biosimilars
Journal Title: Generics and Biosimilars Initiative Journal - Year 2014, Vol 3, Issue 2
Abstract
It is far from clear whether off-patent biological medicines can offer the same cost savings as those offered by off-patent non-biological (chemically derived) medicines, write a group of Brussels-based health economists in the European Journal of Health Economics. Several key factors will play a role in realizing the potential of these effective low-cost agents, including regulatory issues, price and reimbursement policies and, ultimately, whether physicians can be assured of their safety and effectiveness [1].
Authors and Affiliations
GaBI Journal Editor
Keywords
Related Articles
- EP ID EP354472
- DOI 10.5639/gabij.2014.0302.025
- Views 88
- Downloads 0
Italy’s final position paper on biosimilars and new price and reimbursement pathway
The AIFA’s position paper recognizes the relevance of biosimilars to ensure the sustainability of drug expenditure but the new price and reimbursement procedure may not favour their prompt market access.
Saving money in the European healthcare systems with biosimilars
Introduction: The use of biotechnological manufactured drugs, or biologicals, has increased massively over the past few years. Used especially in the treatment of cancer and other severe diseases, biologicals incur high...
Legislative efforts to limit prescription information sharing between patients and healthcare providers represent a serious threat to the health and safety of the American nation
Legislation in support of pharmacist notification to patients and providers of substitution of an interchangeable biologic for the originator biologic was recently vetoed in California. Automatic substitution of approved...
Austria increases dialogue in order to involve physicians more with biosimilars
Comment on the GaBI Journal article titled The potential for doctors to contribute to biosimilar guidelines [1] and the GaBI Online article titled Dialogue needed to build confidence in biosimilars [2], both by GaBI Jour...
Critical immunogenicity differences will be obscured by a common INN for biosimilars
Information about variable immunogenicity arising from formulation differences between competing biosimilars is critical for informed judgments by prescribing physicians. Use of a common INN for biosimilars will obfuscat...